Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.57 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 4/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.48 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.48 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.48 |
| ▸ | CPA1 | P15085 | 2/20 | 0.47 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CTSH | P09668 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17728729 | 0.91 | EPHX1 (0.53) | MMECYP1A2EPHX1 | |
| SCHEMBL28208789 | 0.91 | EPHX1 (0.53) | MMECYP1A2EPHX1 | |
| SCHEMBL17728727 | 0.91 | EPHX1 (0.53) | MMECYP1A2EPHX1 | |
| SCHEMBL25831733 | 0.84 | ENPEP (0.41) | MMECYP1A2CYP3A4EPHX1 | |
| SCHEMBL22154657 | 0.84 | ANPEP (0.41) | MMEFFAR1PPARGPPARAEPHX1 | |
| SCHEMBL24140474 | 0.84 | SLC7A5 (0.53) | MMECTSKCTSS | |
| SCHEMBL22154816 | 0.84 | ANPEP (0.41) | MMEFFAR1PPARGPPARAEPHX1 | |
| SCHEMBL27124358 | 0.84 | SLC7A5 (0.53) | MMECTSKCTSS | |
| SCHEMBL25818343 | 0.84 | ENPEP (0.41) | MMECYP1A2CYP3A4EPHX1 | |
| SCHEMBL11969583 | 0.84 | MME (0.64) | MMEACEACE2SRRPSAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11547687-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-04 | — | — | US | disclosed |
| US-10744104-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190262297-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-29 | — | — | US | disclosed |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-20170368010-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20130245260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8449890-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8449890-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| WO-2013067163-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-02 | — | — | US | disclosed |
| WO-2012154249-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885MMEL1 213/4885ACE 3/4885 |
| US-20130109639-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885MMEL1 213/4885ACE 3/4885 |
| US-20170368010-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885MMEL1 213/4885ACE 3/4885 |
| US-11547687-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885MMEL1 213/4885ACE 3/4885 |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885MMEL1 322/4885ACE 5/4885 |
| US-10744104-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885MMEL1 213/4885ACE 3/4885 |
| US-20210059966-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885MMEL1 213/4885ACE 3/4885 |
| US-20190262297-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MME 1/4885MMEL1 213/4885ACE 3/4885 |
| US-20130245260-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885MMEL1 322/4885ACE 5/4885 |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885MMEL1 322/4885ACE 5/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885MMEL1 213/4885ACE 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.